To further examine the effect of SKP2 on Bcr-Abl in vivo, we tested the effect of genetic or pharmacological inhibition of SKP2 on the phosphorylation and overall expression of Bcr-Abl in CML cells with SKP2 shRNA or SKP2-C25, a potent and specific inhibitor of SKP238. The gene discussed is SKP2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.